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ARTICLE
Mutation-Positive and Mutation-Negative Patients with Cowden
and Bannayan-Riley-Ruvalcaba Syndromes Associated with
Distinct 10q Haplotypes
Marcus G. Pezzolesi, Yan Li, Xiao-Ping Zhou, Robert Pilarski, Lei Shen, and Charis Eng
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) encodes a tumor-suppressor phosphatase frequently
mutated in both sporadic and heritable forms of human cancer. Germline mutations are associated with a number of
heritable cancer syndromes that are jointly referred to as the “PTEN hamartoma tumor syndrome” (PHTS) and include
Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Proteus-like syndrome. Germline PTEN
mutations have been identiﬁed in a signiﬁcant proportion of patients with PHTS; however, there are stillmany individuals
with classic diagnostic features for whom mutations have yet to be identiﬁed. To address this, we took a haplotype-based
approach and investigated the association of speciﬁc genomic regions of the PTEN locus with PHTS. We found this locus
to be characterized by three distinct haplotype blocks 33 kb, 65 kb, and 43 kb in length. Comparisons of the haplotype
distributions for all three blocks differed signiﬁcantly among patients with PHTS and controls ( , , andPp .0098 P ! .0001
for blocks 1, 2, and 3, respectively). “Rare” haplotype blocks and extended haplotypes account for two-to-P ! .0001
threefold more PHTS chromosomes than control chromosomes. PTEN mutation–negative patients are strongly associated
with a haplotype block spanning a region upstream of PTEN and the gene’s ﬁrst intron ( ). Furthermore, allelicPp .0027
combinations contribute to the phenotypic complexity of this syndrome. Taken together, these data suggest that speciﬁc
haplotypes and rare alleles underlie the disease etiology in these sample populations; constitute low-penetrance, mod-
ifying loci; and, speciﬁcally in the case of patients with PHTS for whom traditional mutations have yet to be identiﬁed,
may harbor pathogenic variant(s) that have escaped detection by standard PTEN mutation–scanning methodologies.
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Phosphatase and tensin homolog deleted on chromosome
10 (PTEN [MIM 601728]) (also known as “mutated inmul-
tiple advanced cancers 1” [MMAC1] and “tensin-like phos-
phatase 1” [TEP1]) encodes a tumor-suppressor phos-
phatase that signals down the phosphoinositol-3-kinase
(PI3K)/AKT pathway, effecting apoptosis and cell-cycle ar-
rest.1–3 Germline PTEN mutations are primarily associated
with a number of apparently clinically distinct heritable
cancer syndromes jointly referred to as the “PTEN ha-
martoma tumor syndrome” (PHTS).4 These include Cow-
den syndrome (CS [MIM 158350]), Bannayan-Riley-
Ruvalcaba syndrome (BRRS [MIM 153480]), Proteus
syndrome (PS [MIM 176920]), and Proteus-like syndrome
(PLS). All four syndromes are characterized by multiple
hamartomatous lesions affecting derivatives of all three
germ-cell layers. In CS, patients are also at an increased
risk of developing breast, thyroid, and endometrial can-
cer.5,6 To date, germline PTEN mutations have been iden-
tiﬁed in 85% of patients who received a diagnosis of CS
and 65% of patients who received a diagnosis of BRRS.4,7
Additionally, 20% and 50% of patients with PS and PLS,
respectively, have also been shown to carry PTEN germline
mutations.8–10
Mutation scanning of PTEN has primarily focused on
the gene’s nine exons and intron-exon boundaries, which
span ∼103 kb on chromosome subband 10q23.3. Germ-
linemutations have been reported throughout PTEN,with
the exception of exon 9, and the majority of these localize
to its phosphatase catalytic core located in exon 5.1,11More
recently, mutations in the core promoter region of PTEN
have also been identiﬁed and have been found to be as-
sociated with CS and increased phosphorylated AKT lev-
els.7 However, despite the signiﬁcant proportion of pa-
tients with known PTEN mutations, there are still many
individuals with classic PHTS diagnostic features for
whom mutations have yet to be identiﬁed. Notably, CS is
believed to be linked to the PTEN region, without genetic
heterogeneity.12 In BRRS, on the other hand, the extent
of genetic heterogeneity is unknown. Other mechanisms,
such as modiﬁers of PTEN or another gene (or genes) that
have yet to be identiﬁed, may be causal of this syn-
drome.4,13 For individuals with PHTS, particularly those
with CS, and without identiﬁable germline mutations, it
is likely that the molecular mechanism(s) underlying their
disease involves genetic alteration outside of the PTEN
coding sequence, possibly involving elements associated
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in its transregulation or deregulation and which may lie
upstream, downstream, or intronic of PTEN. Identifying
the mechanism of PTEN dysfunction in these patients is
critical and of signiﬁcant importance to the practice of
personalized genetic healthcare.
To aid in identifying these genetic alterations, we used
a haplotype-based approach to investigate the association
of speciﬁc genomic regions of the PTEN locus with disease.
Through this approach, we demonstrate that speciﬁc hap-
lotypes, perhaps acting as low-penetrance susceptibility
loci, are associated with PHTS in PTEN mutation–negative
samples. In addition to furthering our understanding of
the role PTEN has in patients without detectable muta-
tions, we have also identiﬁed speciﬁc haplotypes thatmay
act as low-penetrance alleles, or modifying factors, which
could inﬂuence phenotypic expression in a subset of
CS/BRRS-affected patients with known germline PTEN
mutations.
Material and Methods
Study Subjects
A total of 447 unrelated subjects were included in the current
analysis—94white control subjects, 148white patientswith PHTS
without detectable germline PTEN mutations (i.e., PTEN muta-
tion–negative patients), and 205 white patients with PHTS with
previously identiﬁed germline PTEN mutations/variations (i.e.,
PTENmutation/variation–positive patients). DNA for control sub-
jects (Utah residents with ancestry from northern and western
Europe) was acquired from the Coriell Institute for Medical Re-
search (Camden, NJ). All subjects with PHTS were enrolled by
referral from centers located throughout the United States, Can-
ada, and Europe. Informed consent was acquired for all referred
subjects in accordance with procedures approved by the human
subjects protection committees of each respective institution.
Among the PTEN mutation–negative patients, 94 had classic
CS, 10 had classic BRRS, 4 exhibited features of both CS and BRRS
(termed “CS-BRRS overlap”), and 39 exhibited a CS-like pheno-
type (i.e., had some features of CS but did not meet operational
diagnostic criteria). One PTEN mutation–negative patient could
not be classiﬁed.
The cohort of PTEN mutation/variation–positive patients in-
cluded 103 mutation-positive samples (i.e., samples with path-
ogenic heterozygous missense or nonsense mutations) and 102
variation-positive samples. This latter group consists primarily of
individuals with identiﬁed variants of unknown signiﬁcance lo-
cated in the PTEN core promoter region or within potential splice
donor/acceptor sites. Among the PTEN mutation-positive pa-
tients, 34 had classic CS, 18 had classic BRRS, 10 exhibited features
of CS-BRRS overlap, and 40 were classiﬁed as CS-like. One PTEN
mutation–positive patient could not be classiﬁed. The PTEN var-
iation–positive patients included 39 with classic CS, 2 with classic
BRRS, 6 with both CS and BRRS features, and 52 classiﬁed as
having CS-like phenotype. Three PTEN variation–positive pa-
tients could not be classiﬁed.
All patients classiﬁed as having CS in the current study met
operational criteria established by the International Cowden
Consortium and curated by the National Comprehensive Cancer
Network.6
SNP Genotyping
SNPs spanning the PTEN locus and located ∼1 every 5 kb were
selected from the dbSNP database for validation and estimation
of minor-allele frequency in a 10-sample screening set consisting
of 5 white control subjects and 5 white patient samples. Twenty-
four screened SNPs were found to have a minor-allele frequency
0.10 and met our criteria for inclusion in this study. To achieve
a uniformly spaced SNP map, six additional SNPs with a minor-
allele frequency 0.10 were identiﬁed by DNA resequencing in
our screening set. All 30 SNPs were genotyped in our 447-sample
cohort. PCRs included 12.5 ml HotStarTaq Master Mix (Qiagen),
10 mM forward primer, 10 mM reverse primer, and 20 ng of
template DNA and used the following thermal cyclingconditions:
95C for 15 min, 34 cycles at 95C for 30 s, 50C–58C for 45 s,
and 72C for 1 min, followed by a ﬁnal extension at 72C for 10
min. Twenty-nine SNPs were genotyped using either RFLP,
SNaPshot (Applied Biosystems), or fragment analysis. SNaPshot
and fragment-analysis products were electrophoresed using an
ABI 3730 DNA Analyzer (Applied Biosystems) and were ana-
lyzed using GeneMapper v3.5 software (Applied Biosystems).
rs12573787 was genotyped by direct DNA resequencing. Primer
sequences and genotyping methodologies are provided in ap-
pendix A (online only).
Hemizygous PTEN Deletion Analysis
Real-time quantitative PCR was used to investigate potential mi-
crodeletions in both control ( ) and PTEN mutation–nega-np 4
tive ( ) samples for which homozygosity was observed fornp 14
all 30 SNPs. Fifteen PTEN mutation/variation–positive samples
were also homozygous for SNPs assayed in this region; however,
by virtue of their heterozygous mutations/variations, these sam-
ples are assumed to carry two copies of the PTEN allele. Copy-
number determinations were made for exons 2 and 5 of our target
gene, PTEN, and for exon 7 of a control reference gene, GAPDH.
Four homozygous control samples and four homozygous PTEN
mutation/variation–positive samples were used as negative con-
trols. Additionally, two samples previously determined to have
PTEN deletions (one spanning the entire PTEN locus, the other
spanning both the PTEN and BMPR1A genes) were assayed as
positive controls. PCR efﬁciencies for each amplicon were deter-
mined by standard curve analysis using serial dilutions of ge-
nomic DNA from a control sample (100 ng, 50 ng, 25 ng, and
12.5 ng). The calculated PCR efﬁciencies for these amplicons
ranged from 76% to 81%.
Determination of gene copy number was assayed using 12.5 ml
iQ SYBR Green Supermix (Bio-Rad Laboratories), 10 mM forward
primer, 10 mM reverse primer, and 20 ng of template DNA. Ther-
mal cycling conditions were 95C for 3 min and 40 cycles at 95C
for 30 s followed by 58C for 30 s and 72C for 30 s, with the use
of an ABI 7700 Sequence Detection System (Applied Biosystems).
Target and reference genes were assayed in triplicate for each
sample and were subject to melt-curve analysis to determine am-
plicon speciﬁcity. The relative quantiﬁcation of gene copy num-
ber for both PTEN amplicons was determined using the compar-
ative delta Ct method (2DDCt) as described by Livak et al.14
Linkage Disequilibrium (LD) and Haplotype Analysis
Following assessment of Hardy-Weinberg equilibrium (HWE) at
each polymorphic locus, pairwise LD coefﬁcients (Lewontin’s D′)
were estimated using the LDmax software program and were vi-
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Figure 1. Schematic diagram of the PTEN locus and SNPs included in the current analysis
sualized using the GOLD graphical interface (Gonc¸alo Abecasis’
Software Page).15 D′ was calculated and plotted separately for each
sample population (control subjects, PTEN mutation–negative
patients, and PTEN mutation/variation–positive patients). LD
blocks were determined using data from the control population
and the dynamic programming algorithms implemented in the
HapBlock software program (empirical LD method; for′D 1 0.90
strong LD).16,17 After the block partitioning, haplotype phase was
reconstructed for each block and all genotyped samples by use
of the SNPHAP software program, based on pairwise LD mea-
surements and the expectation-maximization (EM) algorithm,
and the PHASE v2.1 software program, based on a Bayesian
approach.18,19 Additionally, haplotype phase was reconstructed
for the extended 30-SNP haplotype for all samples.
Statistical Analysis
Allele and genotype frequencies were computed for each SNP. P
values for HWE were obtained, and Bonferroni adjustment was
applied, to control the overall type I error rate at 0.05. Each pa-
tient group (sharing the same mutation status) was compared
with the controls in their allele and genotype distributions for
each SNP. Following haplotype reconstruction, haplotypes from
PHASE were selected for comparisons. For each block and the
extended block, a number of tests were performed. First, haplo-
type frequencies in all phenotype groups with distinct mutation
statuses were compared using a Pearson x2 test, where rare hap-
lotypes (expected frequency !5 for any group) were pooled to-
gether to make the x2 approximation accurate as determined by
the criterion of Cochran.20 We applied Bonferroni adjustment to
the four overall tests, using the signiﬁcance level of 0.05/4
(0.0125) for each test. Each pair of groups was then compared
using a Pearson x2 test with the same criterion of pooling the rare
haplotypes. If the result of the overall test is statistically signiﬁ-
cant ( ), the subsequent pairwise tests provide more-spe-P ! .0125
ciﬁc comparisons between groups. The ﬁrst x2 test controls the
overall type I error rate, but we further adjust for multiple tests
between pairs of groups by using 0.05/6 (0.0083) as the signiﬁcant
level for each such test. Following this, we compared groups with
different clinical features in terms of the haplotype frequencies,
using the same approach of an overall Pearson x2 test and sub-
sequent comparisons of each group (one at a time) with the con-
trols, pooling rare haplotypes in each test as described above. The
same set of tests was also performed for the controls and the
subset of patients classiﬁed as mutation positive or mutation neg-
ative. As for the ﬁrst group of tests, we use 0.0125 as the signif-
icance level for each overall test, to adjust for the total number
of blocks (four, including three haplotype blocks and the ex-
tended block), and 0.0125 as the signiﬁcance level for each sub-
sequent pairwise comparison, to adjust for the number of groups
being compared with the control group in turn.
Results
SNP Analysis and Identiﬁcation of Hemizygous Deletions
We developed an informative marker set comprised of 30
relatively evenly spaced SNPs (1 SNP every 5.6 kb, with a
minor-allele frequency 110%) across a 163-kb region span-
ning the entire PTEN locus and including 30 kb of ﬂanking
sequence (ﬁg. 1 and table 1). The majority of identiﬁed
SNPs are intronic (18 of 30), 11 are outside of the gene (7
upstream and 4 downstream), and 1 is located in the 5′
UTR of PTEN. They include 19 transitions, 5 transversions,
and 6 insertion/deletion polymorphisms. Table 2 shows
the allele frequencies for all 30 polymorphisms genotyped
in the control and PHTS-affected patient populations. No
signiﬁcant departures from HWE were observed. Figure 2
summarizes the log10P values from comparisons of allele
frequencies among PTEN mutation–negative, PTEN mu-
tation–positive, and PTEN variation–positive groups ver-
sus the control population. Overall, results from 13 (14%)
of the 90 comparisons were signiﬁcant at the 0.05 level.
Speciﬁcally, the allele frequency of SNP2 differed signiﬁ-
cantly among PTEN mutation–positive samples and con-
trol samples ( ). More strikingly, the allele fre-Pp .0083
quencies of SNPs 10, 12, 14, 19, 24, 25, and 27 were all
signiﬁcantly different from the control population among
the PTEN variation–positive group (P values !.01). Addi-
tionally, SNP16 and SNP17 both achieved statistical sig-
niﬁcance for this same comparison ( andPp .0127 Pp
, respectively)..0123
Of the 447 samples, 33 (7.4%) were found to be ho-
mozygous for all 30 SNPs in our panel, including 4 (4.3%)
of 94 control samples, 14 (9.5%) of 148 PTEN mutation–
negative samples, and 15 (7.3%) of 205 PTEN mutation/
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Table 1. Characteristics of the 30-SNP Panel
SNP dbSNP ID Positiona
Variation
(Major/Minor
Alleles)
Minor-Allele
Frequencyb Locationc
1 rs7085791 89583605 G/T .12 30602
2 rs10887756 89587630 A/T .15 26577
3 rs10887758 89593295 T/C .20 20912
4 rs11202585 89598759 G/C .19 15448
5 ss52090924d 89603299 T/C .20 10908
6 rs11202590 89607699 C/T .14 6508
7 rs1903860 89610190 T/C .13 4017
8 rs12573787 89613696 G/A .14 510
9 rs3216482 89616359 ins/del A .20 IVS12074
10 rs11355437 89629037 del/ins G .40 IVS114725
11 rs2673836 89629942 A/G .29 IVS113820
12 ss52090925d 89634206 C/G .21 IVS19556
13 rs10887763 89645216 A/G .14 IVS21370
14 rs3831732 89645229 ins/del A .39 IVS21382
15 rs12569872 89655492 G/A .14 IVS211645
16 rs1234224 89665276 A/G .32 IVS29974
17 ss52090926d 89666296 del/ins 32 nt .39 IVS28954
18 rs10490920 89675623 T/C .14 IVS3329
19 rs3830675 89680936 ins/del TCTTA .31 IVS4109
20 ss52090927d 89689289 del/ins 16 nt .15 IVS56300
21 rs2299941 89694699 A/G .12 IVS57156
22 ss52090928d 89699396 T/C .21 IVS52459
23 rs2673832 89702453 A/G .14 IVS6457
24 ss52090929d 89710231 T/C .22 IVS7400
25 rs555895 89710887 T/G .31 IVS832
26 rs926091 89711392 C/T .14 IVS8537
27 rs701848 89716725 T/C .39 *614
28 rs10509532 89727534 C/T .14 *12325
29 rs7908337 89743671 T/C .24 *28462
30 rs11202614 89745623 C/T .14 *30414
a SNP position on chromosome 10 according to March 2006 human genome assembly, NCBI
build 36.1 (hg18).
b Frequency in control population.
c Location relative to translation start codon (), PTEN exons (IVS), or translation stop
codon (*).
d SNPs identiﬁed by DNA resequencing in our screening set.
Table 2. Summary of SNP Allele-
Frequency Data for Control Sample and
PHTS-Affected Patient Populations
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
variation–positive samples. Because heterozygousity had
been identiﬁed previously in the PTEN mutation/varia-
tion–positive samples, PTEN copy-numberdeterminations
were made only for the control and PTEN mutation–neg-
ative samples. Elsewhere, we reported that 2DDCt values
close to 1 indicate the presence of two PTEN alleles,
whereas values close to 0.5 indicate hemizygous PTEN de-
letions.7 As shown in ﬁgure 3, the control samples were
found to have average values of forDDCt2 1.09 0.14
PTEN exon 2 and for PTEN exon 5, conﬁrming1.06 0.20
that these samples retain two copies of PTEN. Similarly, a
subset of PTEN mutation/variation–positive samples had
average 2DDCt values of for PTEN exon 2 and0.94 0.14
for PTEN exon 5. Two samples known to har-0.97 0.12
bor hemizygous germline deletions spanning the entire
PTEN locus displayed average values of 0.67 and 0.53 for
the two PTEN amplicons. Twelve homozygous PTEN mu-
tation–negative samples exhibited 2DDCt values similar to
those observed in the control and PTEN mutation/vari-
ation–positive samples (1.14–1.66 for PTEN exon 2 and
0.95–1.51 for PTEN exon 5). Two samples, 1582-02 (0.46
for PTEN exon 2 and 0.21 for PTEN exon 5) and 2849-01
(0.72 for PTEN exon 2 and 0.57 for PTEN exon 5), had
2DDCt values that were consistent with hemizygous dele-
tions. Because of their hemizygous status at this locus,
both 1582-02 and 2849-01 were excluded from the sub-
sequent LD and haplotype analyses.
LD along the PTEN Locus
We found three distinct haplotype blocks characterized
by strong LD in the control population (ﬁg. 4A). Block 1
spans SNP1 (30602 G/T) to SNP9 (IVS12074insA) (33
kb), block 2 spans SNP11 (IVS113820 A/G) to SNP21
(IVS57156 A/G) (65 kb), and block 3 spans SNP23
(IVS6457 A/G) to SNP30 (*30414 C/T) (43 kb). Adjacent
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Figure 2. Summary of SNP allele-frequency P values for PHTS-affected patient populations versus the control population. Allele
frequencies among three PHTS-affected patient populations (PTEN mutation–negative, PTEN mutation–positive, and PTEN variation–
positive groups) were compared with the control population for all 30 SNPs by use of a Pearson x2 test. The log10 of the P values
was plotted for each comparison and for all SNPs. Note that log10 P value of 1 p P value of .1, log10 P value of 2 p P value of
.01, and log10 P value of 3 p P value of .001.
to each partitioned block, LD decays. SNP10 (IVS114725
delG) displayed average D′ values of 0.75 and 0.85 with
blocks 1 and 2, respectively, and could not be assigned to
either block. Similarly, SNP22 (IVS52459 T/C) had an
average and was not in strong LD with either′D ! 0.90
adjacent block, suggesting that both SNPs lie in or near
putative recombination hotspots. The PTEN haplotype
structure in two PHTS-affected patient populations (146
unrelated PTEN mutation–negative and 205 unrelated
PTEN mutation/variation–positive PHTS samples) is
shown in ﬁgure 4B and 4C, respectively. Similar to the
control population, signiﬁcant LD was observed for the
entire region. However, compared with in controls, the
overall LD patterns observed in the PHTS samples appear
to be distinct. LD in these samples suggests less recom-
bination of the adjacent blocks and the presence of ex-
tended haplotypes across this locus.
Haplotype Association Analysis at the PTEN Locus
Having identiﬁed three regions of strong LD ﬂanked by
two apparent recombination hotspots, we next proceeded
to investigate the haplotypes contained within each LD
block. Haplotype phase was reconstructed using both the
SNPHAP and PHASE software programs. The two algo-
rithms performed similarly, and agreement was reached
for 98.8% of the reconstructed haplotype blocks and for
96.5% of the reconstructed chromosomes (i.e., extended
haplotypes) (data not shown). PHASE haplotype blocks
and haplotype-block frequencies for all chromosomes are
shown in table 3. The number of common haplotypes
accounting for 180% of the observed chromosomes varied
among the three blocks. We identiﬁed ﬁve common hap-
lotypes for both block 1 and block 2 and a total of seven
common haplotypes for block 3. For block 3, the number
of common haplotypes also varied among sample groups.
The haplotype distributions for each block differed sig-
niﬁcantly among the examined groups (table 3).
The distribution of the ﬁve block 1 haplotypes among
controls, PTEN mutation–negative patients, PTEN muta-
tion–positive patients, and PTEN variation–positive pa-
tients was signiﬁcantly different ( ; ).2x p 30.66 Pp .0098
Haplotype 1 was found to be underrepresented in PTEN
mutation–negative samples (49.7%) and overrepresented
in the control population (63.8%). Haplotype 2 was ov-
errepresented in PTEN mutation–negative and PTEN mu-
tation–positive samples compared with both control and
PTEN variation–positive samples (18.2% and 16.5% vs.
12.2% and 12.3%, respectively). Interestingly, the per-
centage of low-frequency haplotypes was also overrepre-
sented among both PTEN mutation–negative and PTEN
variation–positive samples (10.3% and 8.8%, respectively)
compared with controls (2.7%).
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Figure 3. Hemizygous PTEN deletion analysis. PTEN copy number was estimated at exons 2 and 5 by use of the Livak method for
control ( ), PTEN mutation/variation–positive ( ), and PTEN mutation–negative ( ) samples found to be homozygousnp 4 np 4 np 14
for all 30 genotyped SNPs, as well as for known PTEN deletion–positive samples ( ). The 2DDCt values for the control samplesnp 2
ranged from 0.87 to 1.38. PTEN mutation/variation–positive samples (known to have heterozygous PTEN mutations/variations) displayed
values between 0.75 and 1.13. PTEN deletion–positive samples had average (AVG) 2DDCt values of 0.67 and 0.53 for exons 2 and 5,
respectively. Twelve PTEN mutation–negative samples had values similar to those of the control and PTEN mutation–positive samples
(0.95 to 1.66). Two PTEN mutation–negative samples (1582-02 and 2849-01) displayed 2DDCt values similar to those of the PTEN
deletion–positive samples, ranging from 0.21 to 0.72.
Statistically signiﬁcant differences were also observed
for the haplotype distributions of blocks 2 and 3 between
the examined sample populations ( and 62.53,2x p 45.31
respectively; for both comparisons). For block 2,P ! .0001
haplotype 1 was underrepresented in both the PTEN mu-
tation–negative samples (19.2%) and the PTEN mutation–
positive samples (21.4%) compared with control subjects
(29.3%). Haplotype 2 was the most frequent haplotype
among the PTEN variation–positive samples (32.4%) and
was overrepresented in this group compared with both
control and PTEN mutation–negative samples (15.4% and
16.4%, respectively). The converse was observed for hap-
lotype 4; a 9.8% haplotype frequency was seen in the
PTEN variation–positive samples, compared with 21.3%
and 20.2% in the control and PTEN mutation–negative
samples, respectively.
As observed for block 1, low-frequency haplotypes were
also overrepresented in PHTS samples. These haplotypes
were overrepresented in both PTEN mutation–negative
and PTEN mutation–positive samples compared with con-
trols for block 2 (8.9% and 9.2% vs. 3.7%, respectively).
For block 3, low-frequency haplotypes were only repre-
sented in the three PHTS sample groups (2.7% in PTEN
mutation–negative samples, 2.4% in PTEN mutation–
positive samples, and 5.4% in PTEN variation–positive
samples).
Block 3–haplotype 2 was underrepresented in PTEN var-
iation–positive samples (9.8%) and overrepresented in the
control (21.3%) and PTEN mutation–negative (20.5%)
populations. As discussed above for block 2–haplotypes 2
and 4 among these same three sample populations, block
3–haplotype 6 also displayed an inverse relationship with
block 3–haplotype 2 in PTEN variation–positive samples
(19.1%) compared with the control (6.9%) and PTEN mu-
tation–negative (6.5%) samples. This observation suggests
that a founder haplotype is formed by the extended hap-
lotype between blocks 2 and 3 (haplotypes 4 and 2, re-
spectively). Furthermore, an extended haplotypemay also
exist between block 2–haplotype 2 and block 3–haplotype
6; however, the former appears to be associated withmore
haplotype diversity (table 4).
To explore genetic associations pertaining to extended
haplotypes, we also reconstructed haplotypes spanning all
30 SNPs (table 4). Of all haplotypes observed in our cohort,
10 extended haplotypes represented 81.9%, and 71 ad-
ditional “rare” extended haplotypes accounted for the re-
maining 18.1% (data not shown). Statistically signiﬁcant
differences were observed between the sample popula-
tions ( ; ). Haplotype 2 was observed2x p 77.64 Pp .0001
to be underrepresented in both PTEN mutation–negative
(8.6%) and PTEN mutation–positive (8.7%) samples. This
same haplotype was overrepresented in the PTEN varia-
tion–positive samples (18.6%). Haplotype 5 was overre-
presented in the control population (13.8%) and under-
represented in both the PTEN mutation–negative and
PTEN variation–positive groups (7.5% and 5.9%, respec-
tively). Interestingly, extended haplotype 1, the most fre-
quent haplotype observed in all sampled chromosomes
(16.0%), was underrepresented in PTEN variation–positive
samples (9.3%) compared with both control (18.6%) and
PTEN mutation–negative (19.2%) samples. This haplotype
is comprised of block 2–haplotype 4 and block 3–haplo-
type 2 as well as block 1–haplotype 1 (the most common
haplotype observed in this block:50% in all sample pop-
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Figure 4. GOLD plot of pairwise LD between 30 SNPs. D′ values are reported for all three sample groups: 94 control samples (A), 146
PTEN mutation–negative samples (B), and 205 PTEN mutation/variation–positive samples (C). The control samples display three distinct
haplotype blocks: block 1 from SNP1 (30602 G/T) to SNP9 (IVS12074insA), block 2 from SNP11 (IVS113820 A/G) to SNP21
(IVS57156 A/G), and block 3 from SNP23 (IVS6457 A/G) to SNP30 (*30414 C/T). SNP10 (IVS114725delG) and SNP22 (IVS52459
T/C) appear to lie near or within areas of historical recombination. Both the PTEN mutation–negative and the PTEN mutation/variation–
positive samples display varied LD patterns across this locus compared with the control population.
ulations). This strongly suggests that, despite the presence
of two recombination hotspots, a founder haplotype likely
exists for this region of 10q. Two additional extendedhap-
lotypes, 2 and 5, were also observed to be overrepresented
in the control population (13.3% and 13.8%, respectively)
compared with the PTEN mutation–negative group (8.6%
and 7.5%, respectively). Haplotype 2 was also underrep-
resented in PTEN mutation–positive samples (8.7%).
Additionally, as observed for each of the three individual
blocks, the frequencies of “rare” extendedhaplotypeswere
different among the different sample populations, ac-
counting for only 12.8% of control chromosomes, com-
pared with 22.6% and 18.6% of PTEN mutation–negative
and PTEN variation–positive chromosomes, respectively.
These data suggest that rare alleles may underlie the dis-
ease etiology in these sample populations and, more spe-
ciﬁcally in the case of the PTEN mutation–negative group,
may harbor pathogenic variant(s) that escaped detection
by “standard” PTEN mutation–scanning methodologies.
To examine these associations further, we performed a
series of comparative haplotype analyses among PHTS and
control samples for haplotype blocks and the extended
haplotypes (table 5). A signiﬁcant difference was observed
for block 1 between the PTENmutation–negative and con-
trol samples ( ; ) (table 5). For PTEN2x p 18.20 Pp .0027
variation–positive samples, block 2, block 3, and the ex-
tended haplotype all differed signiﬁcantly from the con-
trol population ( , ; ,2 2x p 22.06 Pp .0005 x p 37.96 P !
; and , , respectively). Notably,2.0001 x p 38.84 P ! .0001
the allele frequencies of several individual SNPs compris-
ing these haplotype blocks were signiﬁcantly different
among these same two groups (table 2 and ﬁg. 2). A com-
parison among PTEN mutation–negative and PTEN vari-
ation–positive samples revealed signiﬁcant differences at
these same genomic regions: block 2 ( ;2x p 28.65 P !
), block 3 ( ; ), and the extended2.0001 x p 39.97 P ! .0001
haplotype ( ; ). In a comparison based2x p 44.13 P ! .0001
on stratiﬁcation by clinical diagnoses (table 5), block 2,
block 3, and the extended haplotype were also associated
with patients with CS-like, reaching statistical signiﬁcance
for each of these comparisons ( , ;2x p 18.46 Pp .0024
, ; and , , respec-2 2x p 24.35 Pp .0010 x p 28.02 Pp .0018
tively). A similar trend was observed for this phenotype
when the PTEN mutation–negative and PTEN mutation–
positive groups were combined (block 2: ,2x p 13.60
; block 3: , ; and the ex-2Pp .0587 x p 12.61 Pp .0273
tended haplotype: , ) (table 5). Al-2x p 21.81 Pp .0095
though interesting, only the comparison of the extended
haplotype was statistically signiﬁcant. Additionally, among
PTEN mutation–negative and PTENmutation–positivepa-
tients with CS, block 1 appeared to show an association
with this phenotype ( ; ), although2x p 14.16 Pp .0146
this result did not reach statistical signiﬁcance following
Bonferroni adjustment.
Discussion
PHTS represents an assemblage of phenotypically diverse
syndromes manifested by germline pathogenic mutations
in the PTEN gene. Standard germline mutation scanning
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Table 3. Haplotype Blocks across the PTEN Locus
Block and Haplotypes
Controls
( )anp 188
PTEN Mutation
Negative
( )anp 292
PTEN Mutation
Positive
( )anp 206
PTEN Variation
Positive
( )anp 204
Block 1 haplotypesb:
1. GATGTCTGD .638 .497 .549 .559
2. TTTGTCTGD .122 .182 .165 .123
3. GACCCTCAI .138 .120 .141 .108
4. GTTGTCTGD .027 .055 .073 .074
5. GACCCCTGI .048 .045 .044 .049
Low frequency .027 .103 .029 .088
Block 2 haplotypesc:
1. GCADGAITDIA .293 .192 .214 .255
2. ACADGGITIIA .154 .164 .199 .324
3. ACAIGADTDIA .176 .240 .204 .162
4. AGAIGADTDIA .213 .202 .165 .098
5. ACGDAGICIDG .128 .113 .126 .103
Low frequency .037 .089 .092 .059
Block 3 haplotypesd:
1. ATTCCCTC .176 .226 .214 .157
2. ACTCCCTC .213 .205 .160 .098
3. ATTCTCTC .160 .123 .136 .216
4. ATGTTTCT .144 .154 .150 .098
5. ATGCTCCC .101 .110 .107 .118
6. ATGCTCTC .069 .065 .097 .191
7. GTTCTCTC .138 .089 .117 .069
Low frequency .000 .027 .024 .054
a n p Number of haplotypes.
b ; .2x p 30.66 Pp .0098
c ; .2x p 45.31 P ! .0001
d ; .2x p 62.53 P ! .0001
has identiﬁed causal variants in a majority of patients di-
agnosed with this complex disorder, particularly in pa-
tients who received a diagnosis of CS or BRRS.1,6 Despite
extensive mutation scanning, however, the etiologic var-
iant(s) have yet to be identiﬁed in 15% and 35% of pa-
tients with these two syndromes. To investigate genetic
associations with PTEN in this subset of patients, as well
as to characterize the haplotype architecture of this locus,
we chose to use a case-control haplotype-based approach.
Similar approaches have been used to examine genetic
associations at a growing number of candidate genes.21–23
Haplotype-based approaches are of particular interest,
since most reports of disease-associated mutations de-
scribe variants that directly alter the protein-coding se-
quence of a gene. These studies fail to consider other
mechanisms that may alter gene function and, where mu-
tations are not found, may overlook polymorphisms that
reside outside of the coding region. Such mechanisms in-
clude alterations of gene regulation through the disrup-
tion of trans-acting factor(s) and cis-acting sequence-ele-
ment interactions, resulting in a pathologic state.24
While the mutation spectrum of PTEN in PHTS has been
well studied, its haplotype architecture has not. The extent
of LD across this region has been examined in three pre-
vious studies.25–27 Hamilton et al.26 ﬁrst reported the ex-
istence of two distinct four-marker haplotypes in the gen-
eral population but found no association with prostate
cancer and benign prostatic hyperplasia. A study by Zhang
et al.27 examined the association of this same locus with
smoking initiation and nicotine addiction, by use of ﬁve
haplotype-tagging SNPs (htSNPs) selected using the SNP-
browser software program (Applied Biosystems). In this
study, three haplotype blocks were observed; block 1
spanned 41 kb (from nucleotide position 89606485 to
89647130), block 2 spanned 16 kb (from nucleotide po-
sition 89679301 to 89695409), and block 3 included a
single SNP located at position 89716724. As the authors
noted, this differed slightly from the PTEN haplotype
structure observed by the International HapMap Project.
Most recently, Haiman et al.25 investigated the inﬂuence
of common variations across this region and the risk of
sporadic breast and prostate cancer. Also employing a
htSNP approach, these authors identiﬁed nine common
haplotypes representing 187% of all chromosomes across
123 kb of the PTEN locus. Among these common hap-
lotypes, no strong association was found with either type
of sporadic cancer.
For the present study, haplotype phase was recon-
structed for our samples by use of the SNPHAP software
program, based on pairwise LD measurements and the EM
algorithm.28,29 Previous studies have demonstrated the
appropriateness of the EM algorithm for inference of
haplotypes from data obtained from unrelated individu-
als.28,30–32 Because our analysis relied on statistical infer-
ences of haplotypes from unphased data, we chose to val-
idate this reconstruction by using a second algorithm
based on a Bayesian approach as implemented in the
PHASE software program.19,33 Although the two programs
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Table 4. Extended Haplotypes for All 30 SNPs across the PTEN Locus
PTEN Extended Haplotypes
Total
( )anp 890
Controls
( )anp 188
PTEN Mutation
Negative
( )anp 292
PTEN Mutation
Positive
( )anp 206
PTEN Variation
Positive
( )anp 204
1. GATGTCTGDDAGAIGADTDIACACTCCCTC .160 .186 .192 .155 .093
2. GATGTCTGDIGCADGAITDIATATTCTCTC .119 .133 .086 .087 .186
3. TTTGTCTGDDACAIGADTDIATATTCCCTC .113 .101 .137 .121 .083
4. GACCCTCAIIACGDAGICIDGTATGTTTCT .099 .117 .082 .117 .088
5. GATGTCTGDIGCADGAITDIATGTTCTCTC .092 .138 .075 .107 .059
6. GATGTCTGDIACADGGITIIATATGCTCTC .064 .027 .031 .073 .137
7. GATGTCTGDIACADGGITIIATATGCTCCC .054 .048 .055 .063 .049
8. GACCCCTGIIACADGGITIIATATGCTCCC .044 .048 .038 .044 .049
9. GATGTCTGDDACAIGADTDIATATTCCCTC .039 .059 .048 .029 .020
10. GTTGTCTGDDACAIGADTDIATATTCCCTC .035 .016 .031 .044 .049
Low Frequency .181 .128 .226 .16 .186
NOTE.— ; .2x p 77.64 P ! .0001
a n p Number of haplotypes.
rely on different mathematical approaches, both algo-
rithms performed remarkably similarly.
Our analysis of the LD structure across this region of
10q revealed three distinct haplotype blocks; block 1 spans
33 kb (from nucleotide position 89583605 to 89616359),
block 2 spans 65 kb (from nucleotide position 89629942
to 89694699), and block 3 spans 43 kb (from nucleotide
position 89702453 to 89745623). Block 2 is ﬂanked by
regions of decreased LD, suggesting that SNPs at these sites
lie within areas of chromosome recombination. Our block
partitioning, based on the method by Gabriel et al.,17 par-
tially agreed with that described by Zhang et al.16 However,
on the basis of our data, block 1 described by Zhang et al.
is actually made up of two distinct blocks.16 As previously
mentioned, these authors deﬁned this region by using two
htSNPs. To ensure the accurate characterization of this
region, we chose to empirically assess its haplotype ar-
chitecture, using a high-density set of polymorphic mark-
ers. Because the extent of LD is variable in this region, the
htSNP approach failed to capture all pertinent information
regarding the locus in question, speciﬁcally regarding the
breakdown of LD observed at SNP10 (IVS114725delG)
and SNP22 (IVS52459 T/C). Therefore, a more dense
marker set is required. htSNP approaches are capable of
capturing most haplotype diversity within a population—
that is, ∼90% of all chromosomes in a given population.17
However, for uncommon haplotypes, particularly in cases
where the causal allele is underrepresented, this approach
is limited. Our ﬁnding that “rare” haplotype blocks ac-
count for two-to-threefold more PHTS chromosomes than
control chromosomes and “rare” extended haplotypes ac-
count for nearly twofold more PTEN mutation–negative
and PTEN variation–positive chromosomes suggests that,
for rare diseases such as PHTS, low-frequency, or “rare,”
haplotypes are the ones associated with disease and may
harbor pathogenic variants.
In our effort to characterize the haplotype architecture
of the PTEN locus, we identiﬁed two PHTS-affected pa-
tients, 1582-02 and 2849-01, with hemizygous microde-
letions. Each retained only a single copy of the PTEN allele;
1582-02 retained extended haplotype 4, and 2849-01 re-
tained extended haplotype 5. These haplotypes had allele
frequencies of 9.9% and 9.2%, respectively, in the entire
sample population, resulting in a !1% chance of homo-
zygosity for these alleles. By contrast, three of the four
homozygous control samples were homozygous for the
most frequent haplotype observed in our study. On the
basis of the analysis of microsatellite markers, these de-
letions span !∼312 kb to 390 kb, respectively (data not
shown). Previously, we identiﬁed PTEN deletions in only
three patients with PHTS, all of whom were clinically
diagnosed with BRRS or CS/BRRS overlap.7 The patients
identiﬁed in the current study have diagnoses of classic
CS (2849-01) and CS-like phenotype (1582-02). Implica-
tions from these data extend to the clinical realm, sug-
gesting that PTEN deletion analysis is warranted in all
PHTS-affected patients with CS, BRRS, CS/BRRS, and CS-
like phenotypes who lack apparent germline mutations.
Interestingly, one PTEN mutation–negative sample was
homozygous for a “rare” extended haplotype with an al-
lele frequency !0.7% in the entire study population. Close
inspection of this haplotype revealed that blocks 2 and 3
were relatively common, whereas block 1 consisted of a
low-frequency block. This low-frequency haplotype block,
GACCCTCGI, was only observed in eight samples: seven
PTEN mutation–negative samples and one PTEN varia-
tion–positive sample. Carriers of this allele include four
patients with CS, three patients with CS-like, and one pa-
tient with CS/BRRS. For our homozygous sample, this sug-
gests that, because of the locations of our amplicons, our
deletion analysis may have been unable to detect a pos-
sible deletion of the 5′ region of this locus. These data
implicate the GACCCTCGI block as a low-frequency,
highly penetrant PHTS-susceptibility allele. Furthermore,
all eight samples have similar “rare” extended haplotypes;
ﬁve (three CS and two CS-like) share the same haplotype,
one (CS/BRRS) deviates from this haplotype by a single
variation in block 2, and two (one CS and one CS-like)
are variable for both block 2 and block 3. Although the
SNPs that make up this block and extended haplotype are
not causal (based on their frequency in the control pop-
ulation), they are likely in LDwith an unknown functional
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Table 5. Comparative Haplotype Analysis
Comparison
Block 1 Block 2 Block 3
Extended
Haplotype
x2 P x2 P x2 P x2 P
Mutation statusa:
PTEN Mut vs. control 18.20 .0027 12.03 .0614 10.44 .1649 17.27 .0447
PTEN Mut vs. control 6.78 .2376 9.66 .0854 8.67 .2771 13.34 .2054
PTEN Var vs. control 12.34 .0304 22.06 .0005 37.96 !.0001 38.84 !.0001
PTEN Mut vs. PTEN Mut 10.91 .0531 3.41 .7566 3.83 .7987 13.05 .2899
PTEN Mut vs. PTEN Var 5.02 .5415 28.65 !.0001 39.97 !.0001 44.13 !.0001
PTEN Mut vs. PTEN Var 8.38 .1364 13.82 .0318 21.65 .0029 20.31 .0161
Clinical featuresb:
Overall 9.32 .3162 29.76 .0193 26.42 .0484 7.98 .0924
CS vs. control 12.36 .0302 7.61 .1788 10.08 .1841 15.51 .1147
BRRS vs. control 1.57 .6667 9.87 .0789 10.03 .1233 5.07 .4065
CS/BRRS vs. control 1.87 .3932 9.19 .0564 1.31 .8600 .49 .4825
CS-like vs. control 12.94 .0240 18.46 .0024 24.35 .0010 28.02 .0018
Mutation status and clinical featuresc:
Overall 8.82 .0659 13.41 .0984 23.70 .0220 3.58 .4700
PTEN Mut and Mut CS vs. control 14.16 .0146 12.40 .0883 10.12 .0720 11.98 .1519
PTEN Mut and Mut BRRS vs. control .96 .8107 9.04 .1715 9.02 .1083 4.11 .5339
PTEN Mut and Mut CS/BRRS vs. control .70 .4027 .04 .8415 4.32 .1155 .29 .5890
PTEN Mut and Mut CS-like vs. control 11.35 .0449 13.60 .0587 12.61 .0273 21.81 .0095
NOTE.—Signiﬁcant results are indicated in bold type. Mut p mutation positive; Mut p mutation negative; Var p
variation positive.
a Patients with PHTS were stratiﬁed on the basis of their PTEN mutation status and were compared with controls as well
as each other. The Bonferroni-adjusted nominal signiﬁcance level used for this comparison was .P ! .0083
b An overall comparison was made on the basis of stratiﬁcation of clinical features followed by comparisons based on
clinical diagnoses (CS, BRRS, CS/BRRS, or CS-like phenotype) for all patient samples, irrespective of mutation status, which
were compared with controls. The Bonferroni-adjusted nominal signiﬁcance level used for this comparison was .P ! .0125
c Overall comparisons of patient clinical diagnoses among PTEN mutation–negative and PTEN mutation–positive samples
were performed, followed by comparisons made among this group versus control samples on the basis of patient clinical
diagnosis. The Bonferroni-adjusted nominal signiﬁcance level used for this comparison was .P ! .0125
variant conferring disease susceptibility. This further sup-
ports the notion that “rare,” low-frequency alleles (LD
blocks and/or extended haplotypes) may be associated
with disease and should therefore be considered as can-
didate susceptibility alleles in rare disorders.
In addition to an association with rare haplotypes, our
analysis of haplotype blocks and extended haplotypes re-
vealed signiﬁcant differences among the control group
and various patient sample populations. The number
and frequency of common haplotypes needed to cover
180% of the observed chromosomes varied for each of the
three blocks and the extended haplotype. Similar to the
association with rare alleles, these data suggest greater
haplotype diversity among the PHTS-affected patient pop-
ulations compared with the control group and are indic-
ative of a higher degree of recombination of the “ancient
haplotype.” Interestingly, the overall LD pattern observed
in our patient samples appears to indicate the presence of
extended haplotypes. This effect seemed most apparent
when PTEN variation–positive patients were compared
with controls, revealing signiﬁcant differences between
these groups for blocks 2 and 3, as well as for the extended
haplotype, and suggesting less recombination among pa-
tients with PHTS. Furthermore, pairwise comparisons be-
tween groups revealed that the PTEN mutation–negative
and PTEN mutation–positive groups were most similar,
suggesting that different pathogenic variants may have
arisen from similar haplotypic backgrounds. Taken to-
gether, these data indicate that some patients with PHTS—
that is, PTEN mutation–positive individuals and perhaps
PTEN variation–positive individuals—exhibit a haplotype-
founder effect, while others—that is, PTENmutation–neg-
ative individuals—harbor rare extended haplotypes that
have undergone extensive “shufﬂing” of the LD blocks
across this region.
Interestingly, among PTEN mutation–negative samples,
the strongest genetic effect appears to be associated with
haplotypes forming block 1 (a block spanning at least 30
kb upstream of PTEN that includes several kilobasepairs
of the gene’s ﬁrst intron). With the exception of PTEN’s
core promoter and exon 1, this region has not been well
characterized. Screening efforts that have failed to identify
mutations/variations at these sites in this group of patients
suggest that alterations in this region may have a role in
the regulation of PTEN. These likely involve novel regu-
latory elements and contribute to its deregulation.
Various PHTSs, such as BRRS andCS, appear to be caused
by the same PTEN mutations, despite clear differences in
phenotypic presentation.1 The R130X mutation in exon
5, for example, occurs in eight PTEN mutation–positive
patients included in this study. Among these individuals,
three have a clinical diagnosis of CS, two have a clinical
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diagnosis of BRRS, and three have a clinical diagnosis of
CS/BRRS. Both individuals with BRRS are carriers of ex-
tended haplotypes 3 and 10 and exhibit classic features
of BRRS, includingmacrocephaly, lipomas, andpigmented
macules of the penis. The probability of this genotype in
the general population is !0.3%, suggesting that this in-
frequent allelic combination likely contributes to their
phenotype and that low-penetrance functional variants
reside on these loci. Furthermore, although stratiﬁcation
by clinical phenotype was only minimally associatedwith
our haplotypes, correlations from these data becomemore
apparent when the patient’smutation status is considered.
In addition to providing a panel of informative markers
for testing genetic associations at the PTEN locus, our data
strongly suggest that speciﬁc haplotypes along this region
are associated with increased PHTS susceptibility. PTEN
mutation–negative samples lacking traditional mutations
in the PTEN coding sequence possess a signiﬁcantly dif-
ferent haplotype architecture than that of control samples.
Along with an association with block 1 of this locus, “rare”
alleles comprise this architecture and may underlie the
disease etiology in these patients. Furthermore, haplotype
proﬁles in patients with PHTS with knownmutations/var-
iations contribute to the phenotypic complexity of this
syndrome. Although themechanisms underlying these re-
lationships have yet to be elucidated, these data suggest
that associated chromosomal segments likely harbor
variants, potentially involved in the transcriptional reg-
ulation of PTEN, which are both pathogenic and/or mod-
ifying in nature and manifest as low-penetrance disease-
susceptibility alleles.
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